Innate Pharma (IPHA) Set to Announce Earnings on Thursday

Innate Pharma (NASDAQ:IPHAGet Free Report) is scheduled to announce its earnings results before the market opens on Thursday, March 21st. Investors that are interested in participating in the company’s conference call can do so using this link.

Innate Pharma Price Performance

IPHA stock opened at $2.39 on Tuesday. The firm has a 50-day moving average price of $2.61 and a 200-day moving average price of $2.59. Innate Pharma has a 12 month low of $1.81 and a 12 month high of $3.57.

Institutional Trading of Innate Pharma

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Innate Pharma by 27.4% during the first quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock valued at $1,695,000 after acquiring an additional 108,335 shares in the last quarter. Millennium Management LLC grew its holdings in Innate Pharma by 389.8% in the fourth quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock worth $267,000 after purchasing an additional 57,050 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Innate Pharma by 156.3% during the 1st quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock worth $127,000 after acquiring an additional 23,012 shares in the last quarter. Balyasny Asset Management LLC acquired a new stake in Innate Pharma in the 3rd quarter valued at about $32,000. Finally, Citadel Advisors LLC purchased a new position in shares of Innate Pharma during the 2nd quarter worth approximately $42,000. Institutional investors own 0.29% of the company’s stock.

About Innate Pharma

(Get Free Report)

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

Featured Stories

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.